PlainRecalls
FDA Drug Low Class III Terminated

Temozolomide Capsules, 20 mg, packaged in a a) 5-count (NDC 43975-253-05) and b) 14 count (NDC 43975-253-14) bottles, Rx only, Mfd, by: Stason Pharmaceuticals, Inc., Irvine, CA, Dist. By: Amerigen Pharmaceuticals, Lyndhurst, NJ

Reported: January 2, 2019 Initiated: December 20, 2018 #D-0344-2019

Product Description

Temozolomide Capsules, 20 mg, packaged in a a) 5-count (NDC 43975-253-05) and b) 14 count (NDC 43975-253-14) bottles, Rx only, Mfd, by: Stason Pharmaceuticals, Inc., Irvine, CA, Dist. By: Amerigen Pharmaceuticals, Lyndhurst, NJ

Reason for Recall

Failed Dissolution Specifications

Details

Units Affected
3552 bottles
Distribution
Product was distributed to 4 wholesalers and 2 retail accounts who may have further distributed the products.
Location
Lyndhurst, NJ

Frequently Asked Questions

What product was recalled?
Temozolomide Capsules, 20 mg, packaged in a a) 5-count (NDC 43975-253-05) and b) 14 count (NDC 43975-253-14) bottles, Rx only, Mfd, by: Stason Pharmaceuticals, Inc., Irvine, CA, Dist. By: Amerigen Pharmaceuticals, Lyndhurst, NJ. Recalled by Amerigen Pharmaceuticals Inc.. Units affected: 3552 bottles.
Why was this product recalled?
Failed Dissolution Specifications
Which agency issued this recall?
This recall was issued by the FDA Drug on January 2, 2019. Severity: Low. Recall number: D-0344-2019.